The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior


Autoria(s): Fogaca, Manoela V.; Aguiar, Daniele C.; Moreira, Fabricio A.; Guimaraes, Francisco S.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

29/10/2013

29/10/2013

2012

Resumo

Cannabinoid receptor 1 (CB1) agonists usually induce dose-dependent biphasic effects on anxiety-related responses. Low doses induce anxiolytic-like effects, whereas high doses are ineffective or anxiogenic, probably due to activation of Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels. In this study we have investigated this hypothesis by verifying the effects of the CB1/TRPV1 agonist ACEA injected into the prelimbic medial prefrontal cortex (PL) and the participation of endocannabinoids in the anxiolytic-like responses induced by TRPV1 antagonism, using the elevated plus-maze (EPM) and the Vogel conflict test (VCT). Moreover, we verified the expression of these receptors in the PL by double labeling immunofluorescence. ACEA induced anxiolytic-like effect in the intermediate dose, which was attenuated by previous injection of AM251, a CB1 receptor antagonist. The higher and ineffective ACEA dose caused anxiogenic- and anxiolytic-like effects, when injected after AM251 or the TRPV1 antagonist 6-iodonordihydrocapsaicin (6-I-CPS), respectively. Higher dose of 6-I-CPS induced anxiolytic-like effects both in the EPM and the VCT, which were prevented by previous administration of AM251. In addition, immunofluorescence showed that CB1 and TRPV1 receptors are closely located in the PL These results indicate that the endocannabinoid and endovanilloid systems interact in the PL to control anxiety-like behavior. (C) 2012 Elsevier Ltd. All rights reserved.

CAPES

CAPES

CNPq

CNPq

FAPESP

FAPESP [07/03685-2]

Identificador

NEUROPHARMACOLOGY, OXFORD, v. 63, n. 2, supl. 4, Part 1-2, pp. 202-210, AUG, 2012

0028-3908

http://www.producao.usp.br/handle/BDPI/36117

10.1016/j.neuropharm.2012.03.007

http://dx.doi.org/10.1016/j.neuropharm.2012.03.007

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

OXFORD

Relação

NEUROPHARMACOLOGY

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #ANANDAMIDE #ANXIETY #CANNABINOID #CB1 RECEPTORS #PREFRONTAL CORTEX #TRPV1 RECEPTORS #VANILLOID #POTENTIAL VANILLOID TYPE-1 #ACID AMIDE HYDROLASE #DORSOLATERAL PERIAQUEDUCTAL GRAY #ELEVATED PLUS-MAZE #RECEPTOR AGONIST CP-55,940 #CANNABINOID CB1 RECEPTORS #CENTRAL-NERVOUS-SYSTEM #VENTRAL HIPPOCAMPUS #TRPV1 RECEPTORS #PHARMACOLOGICAL CHARACTERIZATION #NEUROSCIENCES #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion